A5104239516- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Neutropenia and Cancer Infections
- Cancer Mechanisms and Therapy
- Gyrotron and Vacuum Electronics Research
- Cancer-related Molecular Pathways
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Screening and Detection
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Neuroblastoma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Generative Adversarial Networks and Image Synthesis
- Glycosylation and Glycoproteins Research
- AI in cancer detection
- Cancer Treatment and Pharmacology
Xuzhou Medical College
2024
The First People’s Hospital of Lianyungang
2024
Tongji University
2017-2024
First Hospital of Jilin University
2012-2024
Soochow University
2021-2024
First Affiliated Hospital of Soochow University
2021-2024
Jilin University
2012-2022
Shanghai Pulmonary Hospital
2017-2022
Nanjing Medical University
2022
Jiangsu Province Hospital
2022
Extensive-disease small-cell lung cancer (ED-SCLC) is characterized by rapid progression and relapse, despite high initial response rates to chemotherapy. The primary objective of this trial was demonstrate the non-inferiority amrubicin cisplatin (AP) combination therapy compared with standard first-line regimen etoposide (EP) for previously untreated ED-SCLC in a Chinese population. When verified, switched from superiority. From June 2008 July 2010, 300 patients were enrolled randomly...
Immune therapy has shown good results in small-cell lung cancer (SCLC), but the impact of immune microenvironment disease is unclear. In this work, we detected expression programmed death 1 (PD-1), PD-ligand (PD-L1), and other biomarkers cancer. We also analyzed correlations between these markers survival SCLC.Protein PD-1, PD-L1, PD-L2, CD3, CD4, CD8, FOXP3 was surgical tissues from 102 SCLC patients by immunohistochemistry.Positive PD-1 on tumor-infiltrating lymphocytes (TILs) found 40.2%...
Background Immunotherapy has revolutionized therapeutic patterns of small cell lung cancer (SCLC). Human leukocyte antigen class II (HLA II) is related to antitumor immunity. However, the implications HLA in SCLC remain incompletely understood. Materials and methods We investigated expression on tumor cells tumor-infiltrating lymphocytes (TILs) by immunohistochemistry staining its association with clinical parameters, immune markers, recurrence-free survival (RFS) 102 patients stage I–III...
Abstract Background: Palbociclib plus an aromatase inhibitor is approved for treatment of patients with ER+/HER2− advanced breast cancer (ABC). In the PALOMA-4 trial, adding palbociclib to letrozole prolonged median progression-free survival in Asian women ABC. Here, we report patient-reported outcomes (PROs) from PALOMA-4. Methods: was a randomized, double-blind, phase 3 trial vs . placebo postmenopausal PROs were longitudinally assessed using Functional Assessment Cancer Therapy–Breast...
There is a lack of well-established biomarkers to predict the efficacy pemetrexed-based chemotherapy. In this prospective phase II study, we investigated correlation folate receptor (FR)-positive circulating tumor cell (CTC) level with clinical outcomes patients advanced non-squamous non-small lung cancer (nsNSCLC) when treated chemotherapy.A total 98 nsNSCLC were enrolled. Peripheral blood was collected from each patient prior initiation treatment. FR-positive CTCs enriched by...
The present study was to investigate the real-world efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC).A total 83 (>65 years) NSCLC who were progressed at least two lines previous systemic recruited retrospectively. Patients treated (12 mg or 10 mg). Efficacy assessed all followed up regularly. Adverse reactions collected during administration. Univariate analysis performed using Log rank test multivariate...
<b><i>Background/Aims: </i></b>Etoposide and cisplatin (EP) chemotherapy is the most frequently used regimen in extensive-stage small-cell lung cancer (SCLC) patients, although side effects (e.g., neutropenia) are high. This study investigates association of <i>MDM2</i> rs2279744 <i>TP53 </i>rs1042522 single-nucleotide polymorphisms (SNPs) with EP-induced grade III/IV neutropenia response to EP SCLC patients. <b><i>Methods:...
e16146 Background: The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted TKIs, such lenvatinib sorafenib, are approved for 1st-line Sintilimab, a novel selective anti-PD-1 monoclonal antibody, demonstrated encouraging clinical activities trial aims to explore the safety efficacy sintilimab plus anlotinib (a TKI against angiogenesis) Methods: This is single-arm phase 2 study. Eligible Pts with aHCC, BCLC...
Small cell lung cancer (SCLC), an aggressive disease characterized by rapid progression, early relapse and widespread metastasis, accounts for about 13-15% of cases. Despite its initial sensitivity to chemotherapy radiotherapy, SCLC commonly develops resistance these treatments and, as such, has high recurrence rates. In recent years, immunotherapy shown promising antitumor activity the approach tumor treatment been changed, in particular, programmed death receptor-1/ligand 1 (PD-1/L1)...
Background: Immunotherapy (PD-1/PD-L1 antibody) combined with platinum-based chemotherapy has been established as the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Our previous study showed that nab-paclitaxel had promising efficacy later line setting in ES-SCLC. This phase 2 trial aimed to evaluate and safety of camrelizumab (PD-1 plus carboplatin ES-SCLC.Methods: Inclusion criteria included aged 18-75 years, histologically or cytologically confirmed...
4135 Background: Chemotherapy currently serves as the cornerstone for treating metastatic pancreatic cancer (mPC). Nevertheless, survival of patients with mPC remains poor. Besides, efficacy single-agent immune checkpoint inhibitors or antiangiogenesis in treatment is not satisfying. Therefore, it important to explore combination therapy options mPC. This trial was conducted evaluate effectiveness and safety penpulimab combined anlotinib nab-paclitaxel plus gemcitabine (PAAG) Methods: a...
Purpose The overall survival of patients with pancreatic cancer is extremely low. We aimed to establish machine learning (ML) based model accurately predict three-year and prognosis patients. Methods analyzed from the Surveillance, Epidemiology, End Results (SEER) database between 2000 2021. Univariate multivariate logistic analysis were employed select variables. Recursive Feature Elimination (RFE) method on 6 ML algorithms was utilized in feature selection. To construct predictive model,...
Small cell lung cancer (SCLC) is the most devastating type of human cancer. Patients usually present with disseminated disease to many organs (extensive stage). This study was investigate efficacy and safety cellular immunotherapy (CIT) autologous natural killer (NK), γδT, cytokine-induced (CIK) cells as maintenance therapy for extensive-stage SCLC (ES-SCLC) patients. A pilot prospective cohort conducted ES-SCLC patients who had responded initial chemotherapy. received either CIT (CIT...
Small-cell lung cancer (SCLC) has poor prognosis and is prone to drug resistance. It necessary search for possible influencing factors SCLC chemotherapy insensitivity. Therefore, we proposed an mRNA network track the insensitivity in SCLC. Six samples of patients with were recruited RNA sequencing. TopHat2 Cufflinks used make differential analysis. Functional analysis was applied as well. Finally, multidimensional validation verifying results obtained by experiment. This study a trial...
7091 Background: Endostar (recombinant human endostatin) is a novel antiangiogenesis drug developed in China for non-small cell lung cancer (NSCLC). Because of promising efficacy signals, we performed randomized phase II trial to assess the and safety adding endostar first-line standard chemotherapy treatment chemonaive extensive-stage small-cell (SCLC). Methods: Extensive-stage SCLC patients with performance status 0-2 were randomly assigned group (endostar 7.5mg/m 2 D1-D14 carboplatin...
Abstract Background Immune therapy has achieved notable success in cancer treatment. A novel immunocheckpoint, Lymphocyte activing gene-3 (LAG-3), shown promising therapeutic efficacy non-small cell lung (NSCLC). However, literature about LAG-3 small (SCLC) is scarce. We statistically analyzed the correlation of expression with programmed death 1 (PD-1) and ligand (PD-1), its survival predictive significance, possibility becoming a treatment alternative SCLC. Methods In this study, we...
e13051 Background: The group of HER2-negative accounts for 70-80% breast cancer and effective treatments heavily pretreated patients with metastatic are urgently needed. Eribulin mesylate is a non-taxane microtubule dynamics inhibitor distinct mode action which can be used as chemotherapeutic agent after failure anthracycline taxanes treatments. Anlotinib novel multitarget tyrosine kinase targeting VEGFR, PDGFR, FGFR, c-Kit. This study aimed to evaluate the efficacy safety combined treatment...
8564 Background: Impower133 and CASPIAN studies showed that PD-L1 antibody combined with first-line chemotherapy could prolong the overall survival. Our previous study nab-paclitaxel had a promising efficacy as later line setting in ES-SCLC. This phase II trial aimed to evaluate safety of camrelizumab plus carboplatin front-line Methods: Key inclusion factors were18-75 years old, histologically or cytologically confirmed ES-SCLC, ECOG performance status 0-1, no systematic treatment. Patients...